Hepatitis C
Conditions
Brief summary
The Ministry of Health has set the target of eradicating hepatitis C (HCV) in France by 2025. The goal is to validate the feasibility and value of conducting routine HCV screening in hospitalized patients.
Detailed description
The number of undetected HCV-infected persons has been extrapolated to 75,000 according to the results of a 2014 study. Screening efforts have been set up in groups of people said to be at high viral risk: drug users, prisoners, precarious persons or migrants from highly endemic countries. Nevertheless, the concept of universal screening has not yet been adopted by the guardians and the Ministry. It is in this context that "hepatitis free hospital" projects have been carried out in several French cities such as Nice, Nancy and Marseille. The aim of the HOSPI-VHC study is to evaluate the feasibility and efficiency of systematic HCV screening in all medical and surgical departments of 4 National Association of Hepato-Gastroenterologists of General Hospitals (ANGH) hospitals. This pilot project is part of a public health screening program. It will evaluate the interest and usefulness of implementing universal screening in hospitalized patients without taking into account the existence of viral risk factors. This study will also make it possible to evaluate the implementation of a dedicated care pathway: number of patients screened, number of patients referred for consultation and number of patients accepting the consultation.
Interventions
DIAGNOSTIC_TESTHepatitis C testing
Hepatitis C Screening
Sponsors
Centre Hospitalier Intercommunal Creteil
Association Nationale des Hépato-Gastroentérologues des Hôpitaux Généraux
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patient over 18 years of age * Hospitalized during the study period * Non-opposition for participation in the Protocol
Exclusion criteria
* Patients under 18 years of age * Outpatient, long-stay, maternity and intensive care inpatients * Patients refusing blood collection * Patient may not understand the information sheet * Patient under guardianship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| potential patient versus | 7 days | Number of HCV serologies collected compared to the number of patients meeting the inclusion criteria during the study period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| HCV positive | 7 days | Percentage positive for HCV |
| Follow-up | 2 months | Percentage of patients referred for consultation if HCV positive |
| Polymerase chain reaction (PCR) | 7 days | Percentage of HCV PCR positive patients |
| Viral risk factor | 7 days | Percentage of patients with a viral risk factor |
| hepatic fibrosis | 7 days | Percentage of patients with hepatic fibrosis |
| treatment initiation | 2 months | Percentage of patients benefiting from treatment initiation |
Countries
France
Outcome results
None listed